Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — Shareholder Meeting (October 2019)
17 slides from Neurizon Therapeutics's shareholder meeting presentation, Oct 25, 2019
Slide 1: AGM Presentation 25 October 2019
AGM Presentation 25 October 2019 ASX: PAA ACN 094 006 023 1
Slide 2: Corporate Structure
Corporate Structure 100% 100% Pitney Pharmaceuticals Limited Epichem Synthetic Medicinal Chemistry Pitney Pharmaceuticals Focus on Developing and Expected 2019-2020 sales A$ 4.2m+ repurposing a registered drug (Monepantel) in oncology AGM Presentation October 2019 2
Slide 3: Corporate Snapshot
Corporate Snapshot ASX Code: PAA Total Shares on Issue 301,814,647 Market Cap at $0.125 $35M Options (Unlisted) 56,801,956 Cash (as at 30 June 2019) $2.1M Debt (EFIC) $325K Top 20 Own 35% Epichem Revenue Forecast $4.2M Board/Exec Own 9.3% 2019-2020 AGM Presentation October 2019 3
Slide 4: Experienced Board & Management Team
Experienced Board & Management Team Dr. Roger Aston, Executive Chairman Sam Wright, Director & Company Secretary • > 30 years experience in the pharmaceutical and • > 20 years experience in biotech and healthcare. healthcare industries. • Extensive experience in relation to public company • Director
Slide 5: PharmAust Background
PharmAust Background • Lead product is Monepantel (MPL) – a repurposed drug already approved for Veterinary use by Elanco Animal Health (US $10.7b) • PharmAust patented MPL as an anti-cancer drug • Clinical strategy targeting MPL for vet and human applications • Option Agreement with Elanco US Inc f
Slide 6: Mainstay Of Cancer Treatment
Chemotherapy (Global Sales $52B) Mainstay Of Cancer Treatment • Chemotherapy kills rapidly dividing cells • Typically tumour cells replicate more quickly than normal cells and this difference is harnessed in chemotherapy to selectively kill cancer • Side Effects during chemotherapy arise because nor
Slide 7: A Unique Anti-Cancer Paradigm
Monepantel (MPL) In Oncology A Unique Anti-Cancer Paradigm • VERY LOW TOXICITY • ALREADY REGISTERED AS A ON NORMAL CELLS VETERINARY MEDICINE • mTOR REGULATOR ACCESS TO • SIMPLER PATH TO ALLOWS HIGH REGISTRATION REGISTRATION DOSE THERAPY DOSSIER FOR SAFETY, TOXICOLOGY MANUFACTURE VALIDATION IN IN PLA
Slide 8: Elanco Animal Health – Option Agreement
Elanco Animal Health – Option Agreement • Elanco Animal Health (NYSE:ELAN) – MC=$10.7B US • Monepantel compound is owned by Elanco, approved for the treatment of parasitic infections in sheep (patent protection to 2024) • Option Agreement with Elanco to exclusive, worldwide royalty bearing license t
Slide 9: Elanco To Become No.2 In Animal Medicines
Elanco To Become No.2 In Animal Medicines 2015 Elanco strategically enters therapeutic oncology Elanco agree on $7.6billion acquisition of Bayer’s arena by the purchase of Aratana Therapeutics veterinary drugs unit AGM Presentation AGM Presentation OctoberOctober 25th 2019 2019 9
Slide 10: Risk Mitigation In Next Stage Development MPL
RISK MITIGATION IN NEXT STAGE DEVELOPMENT TUMOUR MARKERS IN CANINES RECEIVING MPL HUMAN PROSTATE, LUNG SHOW SIGNIFICANCE IN AND BOWEL CANCER PROGRESSION FREE SIGNIFICANLY SUPPRESSED BY SURVIVAL MPL MPL PROGRESSION FREE CANINE TRIAL BEGINNING SURVIVAL AN FDA APPROVED NOW WILL BE BASIS TO ENDPOINT FOR
Slide 11: Pivotal Phase II Trial in Canine Cancer During 2019
Pivotal Phase II Trial in Canine Cancer During 2019 KEY CLINICAL ENDPOINTS 1.Safety 2.Lack of Toxicity 3.Progression Free Survival 4.Regression 5.Administration by Owner at Home 6.Suppression of Tumour Markers AGM Presentation October 2019 11
Slide 12: Clinical Outcomes To Commercial Opportunities
Clinical Outcomes To Commercial Opportunities Pilot phase II (2017) in lymphoma trial in dogs Shows MPL effective at Progression-Free Survival Using poor formulation Extensive Reformulation Program: 2018 - 2019 Extensive Phase I Program During 2019 Establishes Establishes New, High Dose, Palatable T
Slide 13: >$2 Billion market for approved mTOR Drugs
>$2 Billion market for approved mTOR Drugs Drug Approved Indications Company 2016 Sales (US$m)1 Sirolimus Transplantation Pfizer 170 Transplantation Renal Cell Carcinoma Rapalogues Breast Cancer Novartis/Pfizer >2,000 (Afinitor/Torisel) Pancreatic Neuroendocrine Tumours Mantle Cell Lymphoma 1. Globa
Slide 14: Initial Market - Pets and Cancer
Initial Market -Pets and Cancer 1 in 4 dogs die of cancer - 6 million diagnosed annually in US Pets are living longer (50% dogs > 10 yrs often die of cancer) Significant unmet need for new oncology drugs (US$500m - USD$1b market) Side effects associated with products and treatments are limit
Slide 15: PharmAust – current status and next steps
PharmAust – current status and next steps • Successful $2.0m Rights Issue to existing shareholders completed in April 2019 • Oversubscribed placement primarily to Australian and Singaporean fund management institutions raises $2.4m in October 2019 • Sufficient funds to complete Phase II in dogs as w
Slide 16: AGM Presentation October 2019
AGM Presentation October 2019 16
Slide 17: Disclaimer
Disclaimer This presentation has been prepared by PharmAust Limited (ASX: PAA) (ACN: 094 006 023) (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents
Neurizon Therapeutics — Shareholder Meeting (October 2019) on 6ix